Kyverna Therapeutics (KYTX) Enterprise Value (2023 - 2026)

Kyverna Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$233.0 million for Q1 2026.

• Quarterly Enterprise Value rose 3.98% year-over-year to -$233.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$233.0 million (up 3.98% YoY) and the FY2025 annual result came in at -$279.3 million, up 2.35% from the prior year.
• Enterprise Value was -$233.0 million for Q1 2026 at Kyverna Therapeutics, up from -$279.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$23.0 million in Q3 2023 and bottomed at -$369.8 million in Q1 2024.
• A 4-year average of -$202.6 million and a median of -$233.0 million in 2026 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value plunged 1300.11% — and 2025, when it surged 46.78%.
• Kyverna Therapeutics' Enterprise Value stood at -$57.5 million in 2023, then slumped by 396.98% to -$286.0 million in 2024, then advanced by 2.35% to -$279.3 million in 2025, then gained by 16.56% to -$233.0 million in 2026.
• Business Quant data shows KYTX's Enterprise Value at -$233.0 million in Q1 2026, -$279.3 million in Q4 2025, and -$171.1 million in Q3 2025.